La combinazione basata sulla formulazione sottocutanea (SC) di TALVEY®▼ (talquetamab) e DARZALEX® (daratumumab) evidenzia risposte profonde e durature in pazienti con mieloma multiplo recidivato o refrattario
01 oct. 2024 09h17 HE
|
Janssen Cilag International NV
I dati aggiornati evidenziano una percentuale del 100 per cento di risposta complessiva, con il 56 per cento dei pazienti che ha ottenuto una risposta completa o migliore con il dosaggio settimanale,...
L'association TALVEY®▼ (talquetamab) et DARZALEX® (daratumumab) en sous-cutané (SC) montre des réponses profondes et durables chez les patients atteints d'un myélome multiple récidivant ou réfractaire
01 oct. 2024 09h17 HE
|
Janssen Cilag International NV
Les données mises à jour présentent un taux de réponse global de 100 pour cent, parmi lesquels 56 pour cent des patients ont obtenu une réponse complète ou supérieure avec un schéma d'administration...
Kombination aus TALVEY®▼ (talquetamab) und DARZALEX® (daratumumab) in subkutaner (s. c.) Formulierung zeigt tiefgreifendes und dauerhaftes Ansprechen bei Patienten mit rezidiviertem oder refraktärem Multiplem Myelom
01 oct. 2024 09h17 HE
|
Janssen Cilag International NV
Aktuelle Daten zeigen 100 Prozent Gesamtansprechrate, wobei 56 Prozent der Patienten bei wöchentlicher Verabreichung ein komplettes Ansprechen oder besser erreichten, was die Kombinierbarkeit des...
CARVYKTI® ▼ (ciltacabtagene autoleucel; cilta-cel) ist die erste Zelltherapie, die das Gesamtüberleben von Patienten mit multiplem Myelom bereits in der Zweitlinienbehandlung im Vergleich zu Standardtherapien signifikant verlängert
30 sept. 2024 12h08 HE
|
Janssen Cilag International NV
45-prozentige Verringerung des Sterberisikos durch cilta-cel im Vergleich zu Standardtherapien nach dreijähriger Nachbeobachtung in der bahnbrechenden CARTITUDE-4-Studie1 Die Daten wurden auf der...
CARVYKTI® ▼ (ciltacabtagene autoleucel ; cilta-cel) est la première thérapie cellulaire à augmenter de manière significative la survie globale par rapport aux thérapies standard chez les patients atteints d’UN myélome multiple dès le traitement de deuxième intention
30 sept. 2024 11h59 HE
|
Janssen Cilag International NV
L’étude de référence CARTITUDE-41 a révélé que, au terme d’un suivi de trois ans, le risque de décès a diminué de 45 pour cent avec le traitement par cilta-cel par rapport aux thérapies standards Ces...
CARVYKTI® ▼ (ciltacabtagene autoleucel; cilta-cel) è la prima terapia cellulare a prolungare significativamente la sopravvivenza globale rispetto alle terapie standard per i pazienti con mieloma multiplo già in seconda linea
30 sept. 2024 11h48 HE
|
Janssen Cilag International NV
Riduzione del 45 per cento del rischio di morte ottenuta con cilta-cel rispetto alle terapie standard dopo tre anni di follow-up dello studio di riferimento CARTITUDE-41 I dati sono stati resi...
European Commission approves Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
30 sept. 2024 04h58 HE
|
Janssen Cilag International NV
With this approval, Yuvanci® is the only single tablet combination therapy for treatment for patients with PAH in Europe Johnson & Johnson’s comprehensive PAH portfolio now covers all...
CARVYKTI® ▼ (ciltacabtagene autoleucel; cilta-cel) is the first cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
27 sept. 2024 16h35 HE
|
Janssen Cilag International NV
45 percent reduction in risk of death achieved with cilta-cel versus standard therapies after three-year follow-up in landmark CARTITUDE-4 study1 Data featured in a late-breaking oral...
DARZALEX® (daratumumab) subcutaneous (SC) formulation-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned
27 sept. 2024 13h05 HE
|
Janssen Cilag International NV
Study demonstrates a minimal residual disease (MRD)-negativity rate of 60.9 percent and 43 percent reduction in the risk of progression or death1 Phase 3 CEPHEUS study results presented in...
TALVEY®▼ (talquetamab) and DARZALEX® (daratumumab) subcutaneous (SC) formulation-based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
27 sept. 2024 08h21 HE
|
Janssen Cilag International NV
Updated data show 100 percent overall response rate, with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific...